Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.

Richter syndrome chronic lymphocytic leukemia diffuse large B-cell lymphoma genomics immune checkpoint immune checkpoint inhibitor microenvironment

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 14 08 2020
accepted: 03 11 2020
entrez: 31 12 2020
pubmed: 1 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

Richter Syndrome (RS) is defined as the development of an aggressive lymphoma in the context of Chronic Lymphocytic Leukemia (CLL), with a Diffuse Large B-Cell Lymphoma (DLBCL) histology in 95% cases. RS genomic landscape shares only a few features with We reviewed available PubMed literature about RS genomics, PD-1/PD-L1 (Programmed Death 1/Programmed Death Ligand 1) pathway triggering and subsequent new therapeutic options. Data from about 207 patients from four landmark papers were compiled to build an overview of RS genomic lesions and point mutations. A number of these abnormalities may be involved in tumor microenvironment reshaping. T lymphocyte exhaustion through PD-L1 overexpression by tumor cells and subsequent PD-1/PD-L1 pathway triggering is frequently reported in solid cancers. This immune checkpoint inhibitor is also described in B lymphoid malignancies, particularly CLL: PD-1 expression is reported in a subset of prolymphocytes from the CLL lymph node proliferation centers. However, there is only few data about PD-1/PD-L1 pathway in RS. In RS, PD-1 expression is a hallmark of recently described « Regulatory B-cells », which interact with tumor microenvironment by producing inhibiting cytokines such as TGF-β and IL-10, impairing T lymphocytes anti-tumoral function. Based upon the discovery of high PD-1 expression on tumoral B lymphocyte from RS, immune checkpoint blockade therapies such as anti-PD-1 antibodies have been tested on small RS cohorts and provided heterogeneous but encouraging results. RS genetic landscape and immune evasion mechanisms are being progressively unraveled. New protocols using targeted treatments such as checkpoint inhibitors as single agents or in combination with immunochemotherapy are currently being evaluated.

Identifiants

pubmed: 33381116
doi: 10.3389/fimmu.2020.594841
pmc: PMC7767850
doi:

Substances chimiques

Neoplasm Proteins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

594841

Informations de copyright

Copyright © 2020 Augé, Notarantonio, Morizot, Quinquenel, Fornecker, Hergalant, Feugier and Broséus.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Immunol Res. 2016 Nov;4(11):910-916
pubmed: 27737878
Br J Haematol. 2013 Oct;163(2):194-204
pubmed: 23961875
Blood. 2017 Jun 29;129(26):3419-3427
pubmed: 28424162
Blood. 2012 Aug 16;120(7):1412-21
pubmed: 22547582
Blood. 2013 Feb 28;121(9):1612-21
pubmed: 23247726
Blood. 2005 Sep 15;106(6):2018-25
pubmed: 15914560
Clin Cancer Res. 2019 Aug 1;25(15):4808-4819
pubmed: 31076547
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Immunol Rev. 2019 Nov;292(1):149-163
pubmed: 31883174
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568-74
pubmed: 23810245
Haematologica. 2010 Sep;95(9):1526-33
pubmed: 20421272
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Immunity. 2011 Aug 26;35(2):169-81
pubmed: 21820330
Nucleic Acids Res. 2019 Jan 8;47(D1):D745-D751
pubmed: 30407521
Clin Cancer Res. 2019 Dec 1;25(23):7004-7013
pubmed: 31481504
J Clin Oncol. 2006 May 20;24(15):2343-51
pubmed: 16710033
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Blood. 2011 Mar 24;117(12):3391-401
pubmed: 21266718
Blood. 2017 Jun 22;129(25):3362-3370
pubmed: 28473407
Blood. 2012 Dec 6;120(24):4783-94
pubmed: 23047824
Int Immunol. 2015 Oct;27(10):521-30
pubmed: 25999597
J Clin Oncol. 2012 Jun 20;30(18):2211-7
pubmed: 22547610
Leukemia. 2020 Mar 17;:
pubmed: 32203141
Hum Pathol. 2016 Aug;54:17-24
pubmed: 27045512
Immunology. 2017 Nov;152(3):357-371
pubmed: 28685821
Hum Pathol. 2018 Jan;71:91-99
pubmed: 29122656
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Expert Rev Anticancer Ther. 2011 Mar;11(3):433-42
pubmed: 21417856
Cancer. 2005 Jan 15;103(2):216-28
pubmed: 15578683
Cancer Cell. 2011 Dec 13;20(6):728-40
pubmed: 22137796
Leuk Lymphoma. 2013 Feb;54(2):252-4
pubmed: 22897733
J Exp Med. 2014 Oct 20;211(11):2281-95
pubmed: 25311506
Exp Hematol. 2009 Feb;37(2):184-194
pubmed: 19081173
Am J Surg Pathol. 2007 Oct;31(10):1605-14
pubmed: 17895764
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Hematol Oncol. 2010 Jun;28(2):62-7
pubmed: 20014148
Dis Markers. 2010;29(1):47-53
pubmed: 20826917
Nucleic Acids Res. 2015 Jan;43(Database issue):D789-98
pubmed: 25428349
Br J Haematol. 2019 Apr;185(2):370-373
pubmed: 30028010
J Clin Invest. 2017 Mar 1;127(3):772-779
pubmed: 28248202
Mol Immunol. 2019 May;109:20-26
pubmed: 30851633
J Clin Oncol. 2008 Jan 10;26(2):196-203
pubmed: 18182662
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Blood. 2013 Oct 10;122(15):2673-82
pubmed: 24004666
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
J Mol Cell Biol. 2015 Aug;7(4):338-50
pubmed: 26117839
Blood. 2015 Jul 9;126(2):203-11
pubmed: 25800048
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Haematologica. 2016 Oct;101(10):1144-1158
pubmed: 27694502
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789
pubmed: 27398650
Leukemia. 2011 Sep;25(9):1452-8
pubmed: 21606964
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Int J Cancer. 2017 Nov 15;141(10):2082-2092
pubmed: 28758198
J Neurooncol. 2020 Aug;149(1):13-25
pubmed: 32691208
Blood. 2015 Mar 5;125(10):1676-8
pubmed: 25745187
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Cell Rep. 2019 Aug 20;28(8):2169-2181.e4
pubmed: 31433990
PLoS One. 2012;7(4):e35178
pubmed: 22532845
Nat Rev Immunol. 2015 Jan;15(1):45-56
pubmed: 25534622
Nucleic Acids Res. 2013 Jan;41(Database issue):D970-6
pubmed: 23066107
Nat Commun. 2019 Mar 4;10(1):1034
pubmed: 30833558
Br J Haematol. 2020 Sep;190(6):854-863
pubmed: 32519351
Br J Haematol. 2019 Apr;185(2):363-366
pubmed: 30028000
Nature. 2015 Oct 22;526(7574):525-30
pubmed: 26466571
J Natl Cancer Inst. 2015 Nov 17;108(1):
pubmed: 26577528
J Clin Oncol. 2017 May 1;35(13):1437-1443
pubmed: 28418267
Hematol Oncol. 2015 Jun;33 Suppl 1:70-4
pubmed: 26062059
Acta Haematol. 2015;134(4):255-62
pubmed: 26159545
Am J Hematol. 2014 Dec;89(12):E239-43
pubmed: 25196783
Trends Immunol. 2015 Apr;36(4):265-76
pubmed: 25797516
Mayo Clin Proc. 2015 Nov;90(11):1574-83
pubmed: 26541251
J Immunol. 2018 Jan 15;200(2):847-856
pubmed: 29212908
Blood. 2014 Mar 13;123(11):1647-57
pubmed: 24421328
Leuk Lymphoma. 2003;44 Suppl 3:S41-7
pubmed: 15202524
Cancer Discov. 2016 May;6(5):546-59
pubmed: 26928313
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Br J Haematol. 2008 Jun;142(2):202-15
pubmed: 18492108
Hum Pathol. 2008 Jul;39(7):1050-8
pubmed: 18479731
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Leuk Lymphoma. 2019 Jan;60(1):230-233
pubmed: 29745744
Genome Biol. 2003;4(4):R28
pubmed: 12702209
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
Lancet Haematol. 2019 Feb;6(2):e67-e78
pubmed: 30642819
Signal Transduct Target Ther. 2020 Mar 6;5(1):15
pubmed: 32296035
Am J Surg Pathol. 2014 Dec;38(12):1715-23
pubmed: 25025450
Clin Cancer Res. 2009 Jul 1;15(13):4415-22
pubmed: 19509140
J Hematol Oncol. 2013 Sep 30;6(1):74
pubmed: 24283718
Blood. 2018 Jun 21;131(25):2761-2772
pubmed: 29692342
J Exp Med. 2013 Oct 21;210(11):2273-88
pubmed: 24127483
Blood. 2020 Feb 20;135(8):523-533
pubmed: 31790142
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Nucleic Acids Res. 2008 Sep;36(16):5391-404
pubmed: 18701644
Nat Genet. 2011 Dec 11;44(1):47-52
pubmed: 22158541
Semin Cancer Biol. 2014 Feb;24:71-81
pubmed: 24018164
N Engl J Med. 2014 Mar 13;370(11):997-1007
pubmed: 24450857
Am J Surg Pathol. 2018 Jul;42(7):843-854
pubmed: 29762141
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):610-617
pubmed: 29222311
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Mol Cancer Ther. 2018 Mar;17(3):671-676
pubmed: 29237802
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Blood. 2013 Jan 31;121(5):734-44
pubmed: 23223433
Lancet. 2007 Jul 21;370(9583):230-239
pubmed: 17658394
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Blood. 2016 Oct 27;128(17):2109
pubmed: 27789434
J Immunol. 2015 Dec 15;195(12):5667-77
pubmed: 26538392
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Haematologica. 2013 Jun;98(6):953-63
pubmed: 23300177
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Oncol Rep. 2015 Apr;33(4):1908-14
pubmed: 25646811
Mol Biosyst. 2016 Feb;12(2):477-9
pubmed: 26661513
Nat Rev Clin Oncol. 2017 Apr;14(4):203-220
pubmed: 27805626
Br J Haematol. 2013 Sep;162(6):774-82
pubmed: 23841899
Haematologica. 2020 Mar;105(3):765-773
pubmed: 31197071
Cell. 2013 Feb 14;152(4):714-26
pubmed: 23415222
Immunol Lett. 2002 Oct 21;84(1):57-62
pubmed: 12161284
Blood. 2018 Jan 4;131(1):68-83
pubmed: 29118007
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
Int J Cancer. 2012 Jun 15;130(12):3006-10
pubmed: 21796624
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
Blood. 2007 Jan 1;109(1):259-70
pubmed: 16985177
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713
J Clin Invest. 2008 Jul;118(7):2427-37
pubmed: 18551193
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212601

Auteurs

Hélène Augé (H)

Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risque Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
Université de Lorraine, CHRU-Nancy, service d'hématologie clinique, pôle spécialités médicales, Nancy, France.

Anne-Béatrice Notarantonio (AB)

Université de Lorraine, CHRU-Nancy, service d'hématologie clinique, pôle spécialités médicales, Nancy, France.
UMR7365 Ingénierie Moléculaire et Physiopathologie Articulaire (IMOPA), CNRS, Université de Lorraine, Nancy, France.

Romain Morizot (R)

Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risque Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
Université de Lorraine, CHRU-Nancy, service d'hématologie clinique, pôle spécialités médicales, Nancy, France.

Anne Quinquenel (A)

Département d'hématologie, Université de Reims Champagne-Ardenne, Reims, France.
Département d'hématologie clinique, Centre Hospitalier Universitaire de Reims, Reims, France.

Luc-Matthieu Fornecker (LM)

Université de Strasbourg, Inserm, IRFAC/UMR-S1113, Strasbourg, France.
Département d'hématologie clinique, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.

Sébastien Hergalant (S)

Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risque Environnementaux (N-GERE), Université de Lorraine, Nancy, France.

Pierre Feugier (P)

Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risque Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
Université de Lorraine, CHRU-Nancy, service d'hématologie clinique, pôle spécialités médicales, Nancy, France.

Julien Broséus (J)

Inserm UMRS1256 Nutrition-Génétique et Exposition aux Risque Environnementaux (N-GERE), Université de Lorraine, Nancy, France.
Université de Lorraine, CHRU-Nancy, service d'hématologie biologique, pôle laboratoires, Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH